Clinical trials
Refractory B Acute Lymphoblastic Leukemia clinical trials
Below are recruiting refractory b acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 153 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06709469RecruitingPhase 1
CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
Madrid, MadridAges Up to 30 years - NCT04684147RecruitingPhase 2
CNCT19 cell therapy for relapsed or refractory ALL
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Beijing, Beijing MunicipalityAges 18–65 - NCT05667506RecruitingPhase 1/Phase 2
Check CNCT19 cell therapy for relapsed childhood ALL
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hefei, AnhuiAges 3–18 - NCT06559189RecruitingPhase 1
A new CAR T therapy for children with relapsed B-ALL
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
Aurora, ColoradoAges 3 months–30 years - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Los Angeles, CaliforniaAges 15–50 - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT06408194RecruitingPhase 1
CD22 CAR T cells after Kymriah for B-cell cancers
This trial tests a new CAR T-cell therapy that targets CD22, after you've already received or been scheduled for a standard CD19-targeting CAR T-cell therapy (Kymriah). The goal is to see if giving a second type of CAR T cells can help when the first one doesn't work or the cancer returns.
Palo Alto, CaliforniaAges 1–25 - NCT06389305Recruiting
CIK cell therapy for B-cell leukemia after CAR-T failure
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Beijing, Beijing MunicipalityAges 1–39 - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT06316427RecruitingPhase 1/Phase 2
CD7 CAR-T therapy for T-cell cancers that returned
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Beijing, Beijing MunicipalityAges 1–70 - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B cell cancers
This trial tests a new treatment called CLIC-2201 for people with certain types of B cell lymphoma or leukemia that have come back or not responded to previous treatments. It aims to see if this therapy can help control the cancer.
Calgary, AlbertaAges 1 year+ - NCT06207123RecruitingPhase 1/Phase 2
New drug combo for T-cell leukemia or lymphoma
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT06227026RecruitingPhase 1
CAR-T cell therapy for blood cancers that returned
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
Salt Lake City, UtahAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Los Angeles, CaliforniaAges birth–18 years - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Birmingham, AlabamaAges 12 years+ - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years
Hear when a new Refractory B Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory b acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 153 recruiting refractory b acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory b acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory b acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Acute Lymphoblastic Leukemia
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- T-cell Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.